GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives

Simply Wall St.01-16

GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603393795?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-01-16 04:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603393795","market":"sg","top_or_hot":-1,"title":"GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives","media":"Simply Wall St.","content":"<div>\n<p>GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-holdings-wgs-valuation-after-strong-2025-outlook-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-16 04:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-holdings-wgs-valuation-after-strong-2025-outlook-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-holdings-wgs-valuation-after-strong-2025-outlook-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-holdings-wgs-valuation-after-strong-2025-outlook-and","article_id":"2603393795","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-holdings-wgs-valuation-after-strong-2025-outlook-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603393795","pubTimestamp":1768509307,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches and data partnerships.\nSee our latest analysis for GeneDx Holdings.\nDespite a sharp 1 day share price return of 4.8% decline and a 30 day share price return of 26.2% decline that suggest sentiment has cooled after the guidance update, the 1 year total shareholder return of 53.2% and a very large...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings","BK4196":"保健护理服务"},"translate_title":"GeneDx Holdings(WGS)在2025年强劲前景和新的基因组学增长举措后估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":1.5},"content_text":"GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches and data partnerships. See our latest analysis for GeneDx Holdings. Despite a sharp 1 day share price return of 4.8% decline and a 30 day share price return of 26.2% decline that suggest sentiment has cooled after the guidance update, the 1 year total shareholder return of 53.2% and a very large 3 year total shareholder return show that longer term momentum has been strong as GeneDx rolled out new prenatal offerings, expanded its Infinity data platform, and announced partnerships and leadership changes. If GeneDx’s moves in genomics have caught your attention, it may be worth scanning other healthcare names too. Use this moment to review healthcare stocks as potential additions to your watchlist. With GeneDx guiding to higher revenues, reporting positive net income and trading at roughly a 63% discount to the current analyst price target, the key question is whether this pullback signals an opportunity or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 36.5% Undervalued Against the last close of US$104.56, the most followed narrative assigns GeneDx a fair value near US$164.78, framing a sizeable valuation gap that hinges on genomics adoption and data scale.  Ongoing development and enrichment of GeneDx's comprehensive rare disease genomic database strengthens product differentiation, enables premium pricing, and creates high barriers to entry, supporting sustained top-line growth and long-term profitability as data network effects compound.  Read the complete narrative. Curious what kind of revenue ramp, margin lift, and future earnings multiple need to line up to support that gap? The narrative leans on ambitious growth, expanding profitability, and a rich valuation on future earnings that may surprise you. The full set of assumptions is where the real story sits. Result: Fair Value of $164.78 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, risks around reimbursement policy shifts and slower than expected uptake of genomic testing in new pediatric settings could quickly challenge the optimistic assumptions behind this valuation gap. Find out about the key risks to this GeneDx Holdings narrative. Another View: Multiples Paint a Richer Picture While the popular narrative and our internal model suggest GeneDx looks undervalued overall, the P/S ratio of 7.5x tells a tighter story. It sits above the estimated fair ratio of 5.6x, above peers at 5.9x, and far above the wider US healthcare group at 1.3x. This raises questions about how much optimism is already in the price. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:WGS P/S Ratio as at Jan 2026 Build Your Own GeneDx Holdings Narrative If you look at the numbers and reach a different conclusion, or just prefer your own work, you can shape a fresh view in minutes with Do it your way. A great starting point for your GeneDx Holdings research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If GeneDx has you thinking bigger about your portfolio, do not stop here. Broaden your watchlist now so you are not kicking yourself later.  Spot potential deep value by scanning these 875 undervalued stocks based on cash flows that might offer more compelling price tags based on their cash flows. Ride powerful technology shifts by checking out these 24 AI penny stocks that sit at the intersection of AI and rapid business adoption. Tap into high income potential by reviewing these 12 dividend stocks with yields > 3% that could add steadier yield alongside growth names like GeneDx.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603393795","isCrawlerRequest":true}